CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
3 clinical trials · Condition
◉ Watch CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction
| Record | Firm | Date |
|---|---|---|
| Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (NCT06881017) | China Medical University, China | 2025-05-01 |
| Safety and Activity of IMAB362 in Combination With Zoledronic Acid and Interleukin-2 in CLDN18.2-positive Gastric Cancer (NCT01671774) | Astellas Pharma Global Development, Inc. | 2012-10-16 |
| Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer (NCT01630083) | Astellas Pharma Global Development, Inc. | 2012-07-19 |
Track CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction automatically
Every clearance here is in the API, with alerts when new ones post.